New LDL-cholesterol lowering therapies: Pharmacology, clinical trials, and relevance to acute coronary syndromes

Clinical Therapeutics

Volumn 35, Issue 8, 2013, Pages 1082-1098

  Sahebkar, Amirhossein ^a,b   Watts, Gerald F ^c  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Antisense oligonucleotide; Dyslipidemia; Hypercholesterolemia; Monoclonal antibody; Myocardial infarction; Unstable angina

Indexed keywords

ALIROCUMAB; AMG 145; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B; KEXIN; LIPOPROTEIN A; LOMITAPIDE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MIPOMERSEN; MONOCLONAL ANTIBODY; SUBTILISIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; FATTY LIVER; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; MEDLINE; PROSPECTIVE STUDY; REVIEW;

ANTISENSE OLIGONUCLEOTIDE; DYSLIPIDEMIA; HYPERCHOLESTEROLEMIA; MONOCLONAL ANTIBODY; MYOCARDIAL INFARCTION; UNSTABLE ANGINA;

ACUTE CORONARY SYNDROME; ANIMALS; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; CARRIER PROTEINS; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; OLIGONUCLEOTIDES, ANTISENSE; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84882927131     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.06.019     Document Type: Review

References (120)

1. Kolansky D.M. Acute coronary syndromes: morbidity, mortality, and pharmaco-economic burden. Am J Manag Care 2009, 15:S36-S41.
2. Crea F., Liuzzo G. Pathogenesis of acute coronary syndromes. J Am Coll Cardiol 2013, 61:1-11.
3. Wiviott S.D., Cannon C.P., Morrow D.A., et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005, 46:1411-1416.
4. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711-1718.
5. de Lemos J.A., Blazing M.A., Wiviott S.D., et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004, 292:1307-1316.
6. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
7. Yan A.T., Yan R.T., Tan M., et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 2006, 119:676-683.
8. Baigent C., Blackwell L., Emberson J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
9. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
10. Mora S., Glynn R.J., Boekholdt S.M., et al. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). J Am Coll Cardiol 2012, 59:1521-1528.
11. Harper C.R., Jacobson T.A. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007, 18:401-408.
12. Maxwell K.N., Fisher E.A., Breslow J.L. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci U S A 2005, 102:2069-2074.
13. Seidah N.G., Benjannet S., Wickham L., et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 2003, 100:928-933.
14. Maxwell K.N., Breslow J.L. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A 2004, 101:7100-7105.
15. Park S.W., Moon Y.A., Horton J.D. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem 2004, 279:50630-50638.
16. Abifadel M., Varret M., Rabes J.P., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003, 34:154-156.
17. Zhao Z.Y., Tuakli-Wosornu T.A., Lagace L., et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006, 79:514-523.
18. Hooper A.J., Marais A.D., Tanyanyiwa D.M., Burnett J.R. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 2007, 193:445-448.
19. Langhi C., Le May C., Gmyr V., et al. PCSK9 is expressed in pancreatic δδ-cells and does not alter insulin secretion. Biochem Biophys Res Commun 2009, 390:1288-1293.
20. Roubtsova A., Munkonda M.N., Awan Z., et al. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol 2011, 31:785-791.
21. Dubuc G., Chamberland A., Wassef H., et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2004, 24:1454-1459.
22. Maxwell K.N., Soccio R.E., Duncan E.M., et al. Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J Lipid Res 2003, 44:2109-2119.
23. Costet P., Cariou B., Lambert G., et al. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem 2006, 281:6211-6218.
24. Eberlé D., Hegarty B., Bossard P., et al. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 2004, 86:839-848.
25. Li H., Dong B., Park S.W., et al. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem 2009, 284:28885-28895.
26. Langhi C., Le May C., Kourimate S., et al. Activation of the farnesoid X receptor represses pcsk9 expression in human hepatocytes. FEBS Lett 2008, 582:949-955.
27. Kourimate S., Le M.C., Langhi C., et al. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9. J Biol Chem 2008, 283:9666-9673.
28. Benjannet S., Rhainds D., Hamelin J., et al. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and posttranslational modifications. J Biol Chem 2006, 281:30561-30572.
29. Lakoski S.G., Lagace T.A., Cohen J.C., et al. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009, 94:2537-2543.
30. Dubuc G., Tremblay M., Paré G., et al. A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res 2010, 51:140-149.
31. Alborn W.E., Cao G., Careskey H.E., et al. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem 2007, 53:1814-1819.
32. Lambert G., Ancellin N., Charlton F., et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem 2008, 54:1038-1045.
33. Huijgen R., Boekholdt S.M., Arsenault B.J., et al. Plasma PCSK9 levels and clinical outcomes in the TNT, (Treating to New Targets) trial: a nested case-control study. J Am Coll Cardiol 2012, 59:1778-1784.
34. Welder G., Zineh I., Pacanowski M.A., et al. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res 2010, 51:2714-2721.
35. Careskey H.E., Davis R.A., Alborn W.E., et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 2008, 49394-49398.
36. Costet P., Hoffmann M.M., Cariou B., et al. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non additive fashion in diabetic patients. Atherosclerosis 2010, 212:246-251.
37. Rashid S., Curtis D.E., Garuti R., et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking PCSK9. Proc Natl Acad Sci U S A 2005, 102:5374-5379.
38. Schmidt R.J., Ficorilli J.V., Zhang Y., et al. A 15-ketosterol is a liver X receptor ligand that suppresses sterol-responsive element binding protein-2 activity. J Lipid Res 2006, 47:1037-1044.
39. Cariou B., Ouguerram K., Zair Y., et al. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol 2009, 29:2191-2197.
40. Joy T.R. Novel therapeutic agents for lowering low density lipoprotein cholesterol. Pharmacol Ther 2012, 135:31-43.
41. Cariou B., Le May C., Costet P. Clinical aspects of PCSK9. Atherosclerosis 2011, 216:258-265.
42. Do R.Q., Vogel R.A., Schwartz G.G. PCSK9 Inhibitors: potential in cardiovascular therapeutics. Curr Cardiol Rep 2013, 15:345.
43. Marian A.J. PCSK9 as a therapeutic target in atherosclerosis. Curr Atheroscler Rep 2010, 12:151-154.
44. Lambert G., Sjouke B., Choque B., et al. The PCSK9 decade. J Lipid Res 2012, 53:2515-2524.
45. Catapano A.L., Papadopoulos N. The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis 2013, 228:18-28.
46. Chan J.C., Piper D.E., Cao Q., et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A 2009, 106:9820-9825.
47. Ni Y.G., Di M.S., Condra J.H., et al. A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. J Lipid Res 2011, 52:78-86.
48. Dias C.S., Shaywitz A.J., Wasserman S.M., et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol 2011, 60:1888-1898.
49. Giugliano R.P., Desai N.R., Kohli P., et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012, 380:2007-2017.
50. Koren M.J., Scott R., Kim J.B., et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2012, 380:1995-2006.
51. Raal F., Scott R., Somaratne R., et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation 2012, 126:2408-2417.
52. Sullivan D., Olsson A.G., Scott R., et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012, 308:2497-2506.
53. McKenney J.M., Koren M.J., Kereiakes D.J., et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012, 59:2344-2353.
54. Roth E.M., McKenney J.M., Hanotin C., et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012, 367:1891-1900.
55. Stein E.A., Gipe D., Bergeron J., et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012, 380:29-36.
56. Stein E.A., Mellis S., Yancopoulos G.D., et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012, 366:1108-1118.
57. Yu R.Z., Geary R.S., Flaim J.D., et al. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet 2009, 48:39-50.
58. Shan L., Pang L., Zhang R., et al. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. Biochem Biophys Res Commun 2008, 375:69-73.
59. McNutt M.C., Kwon H.J., Chen C., et al. Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J Biol Chem 2009, 284:10561-10570.
60. Du F., Hui Y., Zhang M., et al. Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein. J Biol Chem 2011, 286:43054-43061.
61. Lipovsek D. Adnectins: engineered target-binding protein therapeutics. Protein Eng Des Sel 2011, 24:3-9.
62. Graham M.J., Lemonidis K.M., Whipple C.P., et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res 2007, 48:763-767.
63. Gupta N., Fisker N., Asselin M.C., et al. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One 2010, 5:10682.
64. Lindholm M.W., Elmen J., Fisker N., et al. PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol Ther 2012, 20:376-381.
65. Frank-Kamenetsky M., Grefhorst A., Anderson N.N., et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A 2008, 105:11915-11920.
66. Bennett C.F., Swayze E.E. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010, 50:259-293.
67. Ito M.K. ISIS 301012 gene therapy for hypercholesterolemia: sense, antisense, or nonsense?. Ann Pharmacother 2007, 41:1669-1678.
68. Packard C.J., Demant T., Stewart J.P., et al. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J Lipid Res 2000, 41:305-318.
69. Elovson J., Chatterton J.E., Bell G.T., et al. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J Lipid Res 1988, 29:1461-1473.
70. Hussain M.M., Strickland D.K., Bakillah A. The mammalian low-density lipoprotein receptor family. Annu Rev Nutr 1999, 19:141-172.
71. St-Pierre A.C., Cantin B., Dagenais G.R., et al. Apolipoprotein-B, low-density lipoprotein cholesterol, and the long-term risk of coronary heart disease in men. Am J Cardiol 2006, 97:997-1001.
72. Benn M., Nordestgaard B.G., Jensen G.B., et al. Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study. Arterioscler Thromb Vasc Biol 2007, 27:661-670.
73. Chien K.L., Hsu H.C., Su T.C., et al. Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese. J Lipid Res 2007, 48:2499-2505.
74. Sierra-Johnson J., Fisher R.M., Romero-Corral A., et al. Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population. Eur Heart J 2009, 30:710-717.
75. Gouni-Berthold I., Berthold H.K. Antisense oligonucleotides for the treatment of dyslipidemia. Curr Pharm Des 2011, 17:950-960.
76. Bell D.A., Hooper A.J., Watts G.F., Burnett J.R. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia. Vasc Health Risk Manag 2012, 8:651-659.
77. Thomas T., Ginsberg H. Targeting ApoB as a therapeutic approach for the treatment of dyslipidemia: the potential role of mipomersen. Clin Lipidol 2010, 5:457-464.
78. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 2003, 270:1628-1644.
79. Kastelein J.J., Wedel M.K., Baker B.F., et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006, 114:1729-1735.
80. Akdim F., Stroes E.S., Sijbrands E.J., et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol 2010, 55:1611-1618.
81. Akdim F., Visser M.E., Tribble D.L., et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol 2010, 105:1413-1419.
82. Raal F.J., Santos R.D., Blom D.J., et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 375:998-1006.
83. Visser M.E., Akdim F., Tribble D.L., et al. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res 2010, 51:1057-1062.
84. Stein E., Dufour R., Gagne C., et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of mipomersen as add-on therapy in heterozygous familial hypercholesterolemia patients with coronary artery disease. Eur Heart J 2010, 31:S898.
85. Tardif J.C., Mcgowan M., Ceska R., et al. Apolipoprotein B synthesis inhibition by mipomersen reduces LDL-C when added to maximally tolerated lipid-lowering medication in patients with severe heterozygous hypercholesterolemia. J Am Coll Cardiol 2011, 57:E492.
86. Akdim F., Tribble D.L., Flaim J.D., et al. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J 2011, 32:2650-2659.
87. McGowan M.P., Tardif J.C., Ceska R., et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One 2012, 7:49006.
88. Stein E.A., Dufour R., Gagne C., et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012, 126:2283-2292.
89. Lonardo A., Lombardini S., Scaglioni F., et al. Hepatic steatosis and insulin resistance: does etiology make a difference?. J Hepatol 2006, 44:190-196.
90. Tarugi P., Averna M., Di L.E., et al. Molecular diagnosis of hypobetalipoproteinemia: an ENID review. Atherosclerosis 2007, 195:e19-e27.
91. Wetterau J.R., Zilversmit D.B. A triglyceride and cholesteryl ester transfer protein associated with liver microsomes. J Biol Chem 1984, 259:10863-10866.
92. Hussain MM, Shi J, Dreizen P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res. 200;44:22-32.
93. Hussain M.M., Bakillah A. New approaches to target microsomal triglyceride transfer protein. Curr Opin Lipidol 2008, 19:572-578.
94. Wetterau J.R., Aggerbeck L.P., Bouma M.E., et al. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 1992, 258:999-1001.
95. Rader D.J., Brewer H.B. Abetalipoproteinemia. New insights into lipoprotein assembly and vitamin E metabolism from a rare genetic disease. JAMA 1993, 270:865-869.
96. Wetterau J.R., Gregg R.E., Harrity T.W., et al. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science 1998, 282:751-754.
97. Dhote V., Joharapurkar A., Kshirsagar S., et al. Inhibition of microsomal triglyceride transfer protein improves insulin sensitivity and reduces atherogenic risk in Zucker fatty rats. Clin Exp Pharmacol Physiol 2011, 38:338-344.
98. Cuchel M., Bloedon L.T., Szapary P.O., et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007, 356:148-156.
99. Samaha F.F., McKenney, Bloedon L.T., et al. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2008, 5:497-505.
100. Cuchel M., Meagher E.A., du Toit Theron H., et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013, 381:40-46.
101. Shiomi M., Ito T. MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion. Eur J Pharmacol 2001, 431:127-131.
102. Ueshima K., Akihisa-Umeno H., Nagayoshi A., et al. Implitapide, a microsomal triglyceride transfer protein inhibitor, reduces progression of atherosclerosis in apolipoprotein E knockout mice fed a Western-type diet: involvement of the inhibition of postprandial triglyceride elevation. Biol Pharm Bull 2005, 28:247-252.
103. Chandler C.E., Wilder D.E., Pettini J.L., et al. CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res 2003, 44:1887-1901.
104. Dunbar RL, Bloedon LT, Gadi R, et al. Impact of high doses of the MTP-inhibitor, AEGR-733, on the single dose pharmacokinetics of atorvastatin and rosuvastatin. 2009. Accessed April 28, 2013. http://www.aegerion.com/Collateral/Documents/English-US/ISA_2009_-_PK_high_dose_lomitapide_with_statin.pdf.
105. Duffy D, Bloedon LT, Dunbar RL, et al. Impact of the MTP Inhibitor AEGR-733 on Pharmacokinetics of Statins. 2007. Accessed April 28, 2013. http://www.aegerion.com/Collateral/Documents/English-US/DALM_2007-_effects_of_lomitapide_on_PK_with_statins.pdf.
106. Dunbar RL, Bloedon LT, Duffy D, et al. Impact of the MTP Inhibitor AEGR-733 on pharmacokinetics of fenofibrate. 2007. Accessed April 28, 2013. http://www.aegerion.com/Collateral/Documents/English-US/DALM_2007_-_effects_of_lomitapide_on_PK_with_fenofibrate.pdf.
107. Dunbar RL, Bloedon LT, Gadi R, et al. Impact of High Doses of the MTP-Inhibitor Lomitapide (AEGR-733) on the Single-Dose Pharmacokinetics of Extended-Release Niacin. 2009. Accessed April 28, 2013. http://www.aegerion.com/Collateral/Documents/English-US/ISA_2009_-_PK_high_dose_lomitapide_with_Niacin.pdf.
108. Webster LA. Surface Logix achieves objectives with SLx-4090 in phase 2a clinical trial. 2008. Accessed April 28, 2013. http://www.drugs.com/clinical_trials/surface-logix-achieves-objectives-slx-4090-phase-2a-clinical-trial-3277.html.
109. Aggarwal D., West K.L., Zern T.L., et al. JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs. BMC Cardiovasc Disord 2005, 5:30.
110. Kim E., Campbell S., Schueller O., et al. A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile. J Pharmacol Exp Ther 2011, 337:775-785.
111. Mera Y., Odani N., Kawai T., et al. Pharmacological characterization of diethyl-2-({3-dimethylcarbamoyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl) amino]phenyl}acetyloxymethyl)-2-phenylmalonate (JTT-130), an intestine-specific inhibitor of microsomal triglyceride transfer protein. J Pharmacol Exp Ther 2011, 336:321-327.
112. Hussain M.M., Rava P., Walsh M., et al. Multiple functions of microsomal triglyceride transfer protein. Nutr Metab (Lond) 2012, 9:14.
113. Noguchi T., Kobayashi J., Yagi K., et al. Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: Results from a crossover study. Atherosclerosis 2011, 217:165-170.
114. Troutt J.S., Alborn W.E., Cao G., Konrad R.J. Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels. J Lipid Res 2010, 51:345-351.
115. Mayne J., Dewpura T., Raymond A., et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis 2008, 7:22.
116. Collinson J., Flather M.D., Fox K.A.A., et al. Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK). Eur Heart J 2000, 21:1450-1457.
117. Turpie A.G.G. Burden of disease: medical and economic impact of acute coronary syndromes. Am J Manag Care 2006, 12:S430-S434.
118. Liao J.K., Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005, 45:89-118.
119. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004, 15:109. (III39-III43).
120. Aikawa M., Rabkin E., Sugiyama S., et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001, 103:276-283.